Format

Send to

Choose Destination
See comment in PubMed Commons below
Rev Med Suisse. 2013 Feb 6;9(372):326-30.

[Perioperative management of new antiplatelet drugs].

[Article in French]

Author information

1
Service de médecine interne générale HUG, 1211 Geneve 14. coralie.joris@hcuge.ch

Abstract

The management of antiplatelet drugs in the perioperative setting is based on an individual evaluation of the thrombotic and bleeding risks. When the bleeding risk is deemed low, continuation of the dual antiplatelet therapy is usually recommended, especially in high thrombotic risk settings. When the bleeding risk is deemed moderate, at least one antiplatelet agent should be continued, usually aspirin, and clopidogrel and ticagrelor should be discontinued 5 days and prasugrel 7 days before surgery. In some rare instances of high bleeding risk, discontinuation of aspirin 3 days before surgery is usually acceptable. In high thrombotic settings, bridging with an intravenous antiplatelet drug with a short half-life may be considered.

PMID:
23469401
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center